Highlights

  • Noxopharm shares jump 5.71% to AUD 0.074 on 1 May 2026, extending one month gain to 23%.
  • New data demonstrates efficacy of SOF-16 in patient-derived samples.
  • Anti-inflammatory effects observed in systemic lupus and rheumatoid arthritis studies.
  • Findings contribute to the company’s data package for future regulatory submissions.
  • The global autoimmune disease therapeutics market is expected to reach US$219.6 billion by 2035.

Noxopharm Limited (ASX:NOX) shares are currently trading at AUD 0.074 during the morning session on 1 May 2026, up 5.71%, following the release of new research data linked to its Sofra technology platform. The stock has also recorded a 23.33% increase over the past month, although it remains down 7.50% over the past year, reflecting a mix of recent momentum and broader performance trends.

The latest share price movement coincides with the company announcing new findings that highlight the potential of its SOF-16 active ingredient, particularly in samples derived from patients with autoimmune diseases. The update provides additional insight into how earlier research is progressing towards therapeutic applications.

Company Overview and Technology Platforms

Noxopharm is a clinical-stage biotechnology company focused on developing treatments for cancer and inflammatory diseases. The company operates through two primary technology platforms: Sofra and Chroma.

The Sofra platform is designed to target inflammation and autoimmune conditions, while also having applications in enhancing RNA-based therapies and vaccines. The Chroma platform is focused on oncology.

Noxopharm’s approach involves leveraging proprietary Drug Development capabilities alongside strategic collaborations with research institutions. Through these efforts, the company is building a pipeline of therapeutic candidates aimed at addressing a range of diseases linked to immune system dysregulation.

New Research Expands Understanding of Sofra Applications

The company’s latest update centres on newly released research data demonstrating how the Sofra platform is being translated into potential drug candidates. The findings were shared through a bioRxiv preprint by Professor Michael Gantier of the Hudson Institute of Medical Research, which serves as Noxopharm’s strategic partner in advancing the technology.

This preprint builds on earlier research published in Nature Immunology, which has recorded over 12,000 online accesses. The new manuscript provides further detail on how these foundational findings are being applied in therapeutic development.

Importantly, this marks the first time that SOF-16, the active component of the company’s SOF-SKN drug candidate, has been tested using samples taken from patients with autoimmune diseases.

Efficacy Observed in Systemic Lupus Study

One of the key components of the research involved studying blood samples from patients with systemic lupus erythematosus (SLE), an autoimmune condition characterised by inflammation.

In the study, blood samples from two SLE patients with a genetic mutation causing hypersensitivity of Toll-like receptor 7 (TLR7) were analysed. These samples exhibited higher levels of TLR7-driven inflammation compared to those from healthy individuals.

When treated with SOF-16 in an in vitro setting, the inflammatory response was significantly reduced. The results indicated that the treatment led to an average decrease of more than 90% in inflammatory markers, demonstrating the compound’s anti-inflammatory activity in this context.

Results from Rheumatoid Arthritis Model

In addition to the lupus study, the research also examined samples from patients with rheumatoid arthritis. Synovial fluid collected from affected joints was used to replicate the inflammatory environment associated with the disease.

This fluid was found to trigger a TLR7-mediated inflammatory response in a cell-based model. However, treatment with SOF-16 significantly reduced this response, with results indicating that the inflammatory signal was nearly eliminated under the test conditions.

These findings suggest that the mechanism of action observed in lupus may also extend to other autoimmune conditions, supporting the broader applicability of the Sofra platform.

Implications for Drug Development and Regulatory Pathway

The combined results from these studies contribute to the data package that Noxopharm is preparing for future regulatory submissions. By demonstrating efficacy in patient-derived samples, the research provides additional support for the potential clinical relevance of the company’s drug candidates.

Management noted that the findings illustrate how earlier discoveries are being translated into practical applications, with the Sofra platform showing potential across multiple disease areas beyond its initial focus.

SOF-SKN, which is a topical formulation of SOF-16, is currently being developed for cutaneous lupus erythematosus (CLE), a chronic inflammatory skin condition. The company has also indicated that the technology could be extended to other autoimmune-related skin diseases such as psoriasis and dermatomyositis.

Market Opportunity and Broader Applications

The global market for cutaneous lupus erythematosus is valued at more than USD 3.3 billion and is expected to grow in the coming years. Beyond this initial target, the Sofra platform has potential applications in conditions such as rheumatoid arthritis and diabetes, as well as other diseases linked to immune system dysfunction.

More broadly, the global autoimmune therapeutics market was valued at USD 163.2 billion in 2024 and is projected to reach USD 219.6 billion by 2035. Additionally, the immuno-oncology market is expected to expand significantly over the next decade.

These figures highlight the scale of the opportunity that Noxopharm is targeting through its technology platforms.

What This Means for Investors?

The share price increase on 1 May 2026 appears to be linked to the release of new research data demonstrating the potential of the company’s Sofra platform. The findings provide further validation of the technology, particularly through testing in patient-derived samples.

While the results are based on in vitro studies and represent an early stage of development, they contribute to the broader body of evidence supporting the company’s drug candidates. The progress outlined in the update may be viewed as a step forward in the development pathway.

Investors are likely to continue monitoring how these findings translate into further clinical development and regulatory progress, as well as the expansion of the platform into additional disease areas.